Regenlab USA Inc.

S-1 filed

DRS/A amended

DRS/A amended

DRS/A amended

Regenlab USA Inc. reports improved financial performance in 2024 with revenue increasing to $48.38M (+1.2% YoY), driven by international growth in Europe and select markets, while U.S. sales declined due to channel realignment. The company highlights expanded gross margins (71.4%) from high-margin PRP+HA products, cost optimization reducing G&A and marketing expenses by $1.2M, and increased R&D investment to $3.85M. Strategic partnerships like OPKO Health (Spain/Europe) and MiMedx are expected to restore U.S. growth. Key product lines include PRP kits (61% of revenue) and CellularMatrix (27%), with a focus on regenerative biologics and tissue engineering platforms.

DRS filed

Regenlab USA Inc. reported improved financial performance in 2024, with revenue increasing to $48.38M (+1.2% YoY), driven by growth in Europe and international markets, while U.S. sales declined due to channel realignment. The company achieved a net income of $1.01M in 2024 compared to a $2.95M loss in 2023, supported by cost optimization, gross margin expansion to 71.4%, and R&D investments. Strategic partnerships with MiMedx and OPKO Health, along with new product launches, are expected to drive future growth. The company also secured a $5M SBA-guaranteed loan and remains focused on expanding its regenerative biologics portfolio.